AZD1152-HQPA is a small molecule inhibitor of Aurora B kinase, which is an enzyme involved in the regulation of cell division. It was first discovered in 2006 and has since been studied for its potential as a treatment for various types of cancer.
Chemical name:
The chemical name for AZD1152-HQPA is N-((3-(1H-Pyrazol-4-yl)phenyl)amino)-6-(4-(methylamino)phenyl)-N-methylpyrido[2,3-d]pyrimidine-2-carboxamide.
Molecular formula:
The molecular formula of AZD1152-HQPA is C27H28N8O.
Formula weight:
The formula weight of AZD1152-HQPA is 464.57 g/mol.
CAS No:
The CAS number of AZD1152-HQPA is 722544-51-6.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
AZD1152-HQPA has been primarily developed for the treatment of cancer. It is an inhibitor of Aurora B kinase, which is involved in the regulation of cell division. By inhibiting Aurora B kinase, AZD1152-HQPA may inhibit the proliferation of cancer cells and promote their death.
Potential effects:
Some potential effects of AZD1152-HQPA include:
Product mechanism:
AZD1152-HQPA works by inhibiting Aurora B kinase, which is an enzyme involved in the regulation of cell division. Aurora B kinase is required for proper chromosome segregation during mitosis, and its inhibition can lead to cell cycle arrest and apoptosis. By inhibiting Aurora B kinase, AZD1152-HQPA can induce cell death in cancer cells and inhibit their proliferation.
Safety:
AZD1152-HQPA has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with AZD1152-HQPA.
Side effects:
AZD1152-HQPA can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of AZD1152-HQPA has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 25 to 150 mg/kg. In clinical trials, doses ranged from 100 to 1200 mg once daily. The drug is typically administered orally.
Conclusion:
AZD1152-HQPA is a small molecule inhibitor of Aurora B kinase that has shown potential as a treatment for various types of cancer. By inhibiting Aurora B kinase, AZD1152-HQPA may inhibit the proliferation of cancer cells and promote their death. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of AZD1152-HQPA in treating various types of cancer
